Opposite effects of the CD30 ligand are not due to CD30 mutations: Results from cDNA cloning and sequence comparison of the CD30 antigen from different sources
References (20)
- et al.
Polymerase chain reaction amplification and sequence analysis of human mutant adenine phosphoribosyltransferase genes: The nature of frequency of errors caused by Taq DNA polymerase
Mutation Res.
(1991) - et al.
Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction
Analyt. Biochem.
(1987) - et al.
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
Cell
(1992) - et al.
Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene
Blood
(1988) - et al.
Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines
Blood
(1994) - et al.
A novel protein domain required for apoptosis. Mutational analysis of human fas antigen
J. biol. Chem.
(1993) - et al.
CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
Cell
(1993) - et al.
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death
Cell
(1994) - et al.
The expression of Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
Blood
(1985) - et al.
Human macrophages can express the Hodgkin's cellassociated Ki-1 (CD30)
Am. J. Pathol.
(1989)
Cited by (11)
CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells
2008, American Journal of PathologyCitation Excerpt :Because CD30 ligand and Ki-1 mAb induced identical effects (data not shown), we performed CD30 stimulation with Ki-1 mAb, and control treatment with IgG3, mAb binding was verified by flow cytometric analysis. All cell lines express wild-type CD30 (B. Hirsch and H. Dürkop, unpublished data).20 The pan-caspase inhibitor Z-VAD-FMK (Calbiochem, Schwalbach, Germany) was used at 50 μmol/L.
Systemic and primary cutaneous anaplastic large cell lymphomas
2003, Seminars in HematologyCitation Excerpt :CD30 activation leads to growth arrest in cell lines from ALK-positive ALCL, but causes proliferation in some Hodgkin’s cell lines and some cutaneous ALCL cell lines.38,81,84,95,100 CD30 mutations are not responsible for the different cellular responses to CD30 activation, since a Hodgkin’s line (L540) that proliferates in response to CD30 and an ACLC line (Karpas) that undergoes growth arrest in response to CD30, both have wild-type CD30 genes.51 Little is known about CD30 signaling in ALCL, and some of the data appear to be contradictory.
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease
2003, BloodCitation Excerpt :The previous studies and our present work suggest that t(2;5)+ALCL cells are characterized by the presence of NPM/ALK fusion protein predominantly in the cytoplasm, expression of the CD30 molecules on the cell surface, and high-level expression of Bcl-3 in the nucleus. Because there is no link between the signaling cascades activated by NPM/ALK and those by CD30 stimulation, t(2;5) leading to the generation of NPM/ALK may occur at a stage of T-cell differentiation that expresses CD30, and therefore CD30 expression itself may not be involved in the development of ALCL9; indeed, ALCL as well as HD cells carry the CD30 gene with a germ-line configuration.50 In contrast, theBCL3gene of ALCL cells showed genetic and epigenetic modifications, both of which are likely associated with oncogenesis.
A review of CD30 expression in cutaneous neoplasms
2021, Journal of Cutaneous Pathology